Alvesco Patent Expiration

ALVESCO's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6036942 COVIS Seal configuration for aerosol canister
Apr, 2013

(11 years ago)

US5605674 COVIS Medicinal aerosol formulations
Feb, 2014

(10 years ago)

US5683677 COVIS Medicinal aerosol formulations
Nov, 2014

(9 years ago)

US5775321 COVIS Seal configuration for aerosol canister
Jul, 2015

(9 years ago)

US6006745 COVIS Device for delivering an aerosol
Dec, 2016

(7 years ago)

US5482934 COVIS Pregna-1,4-diene3,20-dione-16-17-acetal-21 esters, process for their preparation, composition, and methods for the treatment of inflammatory conditions
Oct, 2017

(6 years ago)

US6264923 COVIS Medicinal aerosol formulation of ciclesonide and related compounds
May, 2018

(6 years ago)

US6120752 COVIS Medicinal aerosol products containing formulations of ciclesonide and related steroids
May, 2018

(6 years ago)

US8371292 COVIS Use of ciclesonide for the treatment of respiratory diseases
Feb, 2028

(3 years from now)

Alvesco is a drug owned by Covis Pharma Gmbh. It is used for treating asthma and inflammatory conditions in adolescents and adults. Alvesco uses Ciclesonide as an active ingredient. Alvesco was launched by Covis in 2008. It is is available in aerosol, metered form for inhalation use. Its generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Feb 01, 2028 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 20, 2011
M(M-125) Dec 17, 2015

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using CICLESONIDE ingredient

NCE-1 date: 20 October, 2010

Market Authorisation Date: 10 January, 2008

Treatment: Method of treating inflammatory conditions; Maintenance treatment of asthma as prophylactic therapy in adult and adolescent patients 12 years of age and older. patent claims method for treating a resp...


More Information on Dosage

ALVESCO family patents

Family Patents